```
=> d ibib abs hitstr l4 1-1

L4   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2004:2715  HCAPLUS  Full-text
DOCUMENT NUMBER:          140:53415
TITLE:                    Novel complexes of fatty acid esters of
                          polyhydroxyalkanes and pyridine carboxy
                          derivatives
INVENTOR(S):              Weidner, Morten Sloth
PATENT ASSIGNEE(S):       Astion Development A/S, Den.
SOURCE:                   PCT Int. Appl., 70 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2004000333         A1    20031231    WO 2003-DK423           20030620
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2491871            A1    20031231    CA 2003-2491871         20030620
     AU 2003240441         A1    20040106    AU 2003-240441          20030620
     EP 1560589            A1    20050810    EP 2003-729915          20030620
     EP 1560589            B1    20061004
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     CN 1674921            A     20050928    CN 2003-819661          20030620
     JP 2005537238         T     20051208    JP 2004-514590          20030620
     EP 1640011            A1    20060329    EP 2005-19961           20030620
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     AT 341334             T     20061015    AT 2003-729915          20030620
     NZ 537783             A     20061222    NZ 2003-537783          20030620
     ES 2274236            T3    20070516    ES 2003-729915          20030620
     NO 2005000309         A     20050318    NO 2005-309             20050119
     US 20060069131        A1    20060330    US 2005-517592          20050815
     HK 1076395            A1    20061124    HK 2005-110210          20051115
PRIORITY APPLN. INFO.:                        DK 2002-951          A  20020620
                                              US 2002-389879P      P  20020620
                                              EP 2003-729915       A3 20030620
                                              WO 2003-DK423        W  20030620
OTHER SOURCE(S):          MARPAT 140:53415
AB    The present invention relates to novel combinations of fatty acid derivs. and
      pyridine carboxy derivs., including fatty acid esters with glycerol and 3-
      carboxy pyridine derivs. such as niacinamide.  Such combinations have
      surprisingly shown antiviral and anti-microbial activity and the use for the
      treatment of inflammatory conditions and infections is disclosed herein.
IT    59-67-6, Nicotinic acid, biological studies 59-67-6D,
      Pyridine-3-carboxylic acid, derivs. 98-92-0, Niacinamide
```

110-86-1D, Pyridine, derivs. 114-33-0 329-89-5
4314-66-3 4621-66-3, 3-Pyridinecarbothioamide
6556-11-2 7150-23-4, 6-Methoxyniacinamide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(complexes with fatty acid polyhydroxyalkane esters; novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivs. as therapeutic agents for treatment of disease and cosmetics and dietary supplements)

RN 59-67-6 HCAPLUS
CN 3-Pyridinecarboxylic acid (CA INDEX NAME)



RN 59-67-6 HCAPLUS
CN 3-Pyridinecarboxylic acid (CA INDEX NAME)



RN 98-92-0 HCAPLUS
CN 3-Pyridinecarboxamide (CA INDEX NAME)



RN 110-86-1 HCAPLUS
CN Pyridine (CA INDEX NAME)

RN 114-33-0 HCAPLUS
CN 3-Pyridinecarboxamide, N-methyl- (CA INDEX NAME)



RN 329-89-5 HCAPLUS
CN 3-Pyridinecarboxamide, 6-amino- (CA INDEX NAME)



RN 4314-66-3 HCAPLUS
CN 3-Pyridinecarboxamide, N-ethyl- (CA INDEX NAME)



RN 4621-66-3 HCAPLUS
CN 3-Pyridinecarbothioamide (CA INDEX NAME)



RN 6556-11-2 HCAPLUS
CN myo-Inositol, hexa-3-pyridinecarboxylate (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A



PAGE 2-A



RN 7150-23-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-methoxy- (CA INDEX NAME)



IT 502-54-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(complexes with niacinamide; novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivs. as therapeutic agents for treatment of disease and cosmetics and dietary supplements)
RN 502-54-5 HCAPLUS
CN Octanoic acid, 2,3-dihydroxypropyl ester (CA INDEX NAME)



IT 50-70-4D, Sorbitol, fatty acid esters 56-81-5D, Glycerol, fatty acid esters 57-10-3D, Palmitic acid, polyhydroxyalkane esters 57-55-6D, Propylene glycol, fatty acid esters 60-33-3D, Linoleic acid, polyhydroxyalkane esters 107-88-0D, 1,3-Butylene glycol, fatty acid esters 124-07-2D, Caprylic acid, polyhydroxyalkane esters 141-22-0D, Ricinoleic acid, polyhydroxyalkane esters 142-62-1D, Caproic acid, polyhydroxyalkane esters 143-07-7D, Lauric acid, polyhydroxyalkane esters 334-48-5D, Capric acid, polyhydroxyalkane esters 373-49-9D, Palmitoleic acid, polyhydroxyalkane esters 463-40-1D, α-Linolenic acid, polyhydroxyalkane esters 506-26-3D, γ-Linolenic acid, polyhydroxyalkane esters 513-85-9D, 2,3-Butylene glycol, fatty acid esters 544-63-8D, Myristic acid, polyhydroxyalkane esters 544-64-9D, Myristoleic acid, polyhydroxyalkane esters 6217-54-5D, Docosahexaenoic acid, polyhydroxyalkane esters 10417-94-4D, all-cis-5,8,11,14,17-Eicosapentaenoic acid, polyhydroxyalkane esters
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(complexes with pyridine carboxy derivs.; novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivs. as therapeutic agents for treatment of disease and cosmetics and dietary supplements)

RN 50-70-4 HCAPLUS
CN D-Glucitol (CA INDEX NAME)

Absolute stereochemistry.



RN 56-81-5 HCAPLUS
CN 1,2,3-Propanetriol (CA INDEX NAME)



RN 57-10-3 HCAPLUS
CN Hexadecanoic acid (CA INDEX NAME)



RN 57-55-6 HCAPLUS
CN 1,2-Propanediol (CA INDEX NAME)



RN 60-33-3 HCAPLUS
CN 9,12-Octadecadienoic acid (9Z,12Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 107-88-0 HCAPLUS
CN 1,3-Butanediol (CA INDEX NAME)



RN 124-07-2 HCAPLUS
CN Octanoic acid (CA INDEX NAME)

RN 141-22-0 HCAPLUS
CN 9-Octadecenoic acid, 12-hydroxy-, (9Z,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



RN 142-62-1 HCAPLUS
CN Hexanoic acid (CA INDEX NAME)



RN 143-07-7 HCAPLUS
CN Dodecanoic acid (CA INDEX NAME)



RN 334-48-5 HCAPLUS
CN Decanoic acid (CA INDEX NAME)



RN 373-49-9 HCAPLUS
CN 9-Hexadecenoic acid, (9Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 463-40-1 HCAPLUS
CN 9,12,15-Octadecatrienoic acid, (9Z,12Z,15Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 506-26-3 HCAPLUS
CN 6,9,12-Octadecatrienoic acid, (6Z,9Z,12Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 513-85-9 HCAPLUS
CN 2,3-Butanediol (CA INDEX NAME)



RN 544-63-8 HCAPLUS
CN Tetradecanoic acid (CA INDEX NAME)



RN 544-64-9 HCAPLUS
CN 9-Tetradecenoic acid, (9Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 6217-54-5 HCAPLUS
CN 4,7,10,13,16,19-Docosahexaenoic acid, (4Z,7Z,10Z,13Z,16Z,19Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 10417-94-4 HCAPLUS
CN 5,8,11,14,17-Eicosapentaenoic acid, (5Z,8Z,11Z,14Z,17Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RESULTS FROM REGISTRY, CAPLUS, AND USPATFULL

=> d que stat l46
L38 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L40 65 SEA FILE=REGISTRY SSS FUL L38
L41 14 SEA FILE=HCAPLUS ABB=ON L40
L42 4 SEA FILE=HCAPLUS ABB=ON L41 AND (?COSMETIC? OR ?SKIN? OR ?DERM? OR ?INFLAM?)
L43 14 SEA FILE=HCAPLUS ABB=ON L41 OR L42
L44 7 SEA FILE=USPATFULL ABB=ON L41 OR L42
L45 17 DUP REMOV L43 L44 (4 DUPLICATES REMOVED)
L46 16 SEA L45 AND (PRD<20020620 OR PD<20020620)

=> d ibib abs hitstr l46 1-16

L46 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:44145 HCAPLUS Full-text
DOCUMENT NUMBER: 138:55881
TITLE: Preparation of 2-oxo-4-hydroxypyrroles and quinolines as inhibitors of plasminogen activator inhibitor (PAI-1) for treatment of hemostatic and thrombotic disorders.
INVENTOR(S): Folkes, Adrian; Wang, Shouming; Golec, Julian; Vicker, Nigel; Prisbylla, Michael Paul; Mac, Morrison B.; Epshteyn, Sergey Peter; Webb, Robert Remme
PATENT ASSIGNEE(S): Xenova Limited, UK
SOURCE: Brit. UK Pat. Appl., 61 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2372986	A	20020911	GB 2001-1227	20010117 <--
PRIORITY APPLN. INFO.:			GB 2001-1227	20010117 <--

OTHER SOURCE(S): MARPAT 138:55881
GI



I

AB Title compds. [I; X = CHR2, C(R3):C(R4); R2 = H, alkyl, Ar; R3R4C = atoms to form a (substituted) benzene ring; R1 = H, alkyl, (CH2)nAr, unsatd. (substituted) carbocyclyl; n = 1-10; Ar = (substituted) unsatd. carbocyclyl, heterocyclyl; Z = tetrazolyl, CO2R5; R5 = H, alkyl], were prepared Thus, 6-benzo[b]thiophen-3-yl-4-hydroxy-2-oxo-1,2-dihydroquinoline- 3-carboxylic acid Me ester and 8-(4-aminophenoxy)octanoic acid Me ester were refluxed 3 h in m-xylene to give 8-[4-[(6-Benzo[b]thiophen-3-yl-4- hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)amino]phenoxy]octanoic acid Me ester. The latter showed IC50 = 0.270 μM in a fibrin plate assay.

IT 479621-66-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-oxo-4-hydroxypyrroles and quinolines as inhibitors of plasminogen activator inhibitor (PAI-1) for treatment of hemostatic and thrombotic disorders)

RN 479621-66-4 HCAPLUS

CN Octanoic acid, 8-[4-[[(6-benzo[b]thien-3-yl-1,2-dihydro-4-hydroxy-2-oxo-3-quinolinyl)carbonyl]amino]phenoxy]-, methyl ester (CA INDEX NAME)



L46 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:533661 HCAPLUS Full-text
DOCUMENT NUMBER: 127:205815
ORIGINAL REFERENCE NO.: 127:40015a,40018a
TITLE: Preparation of sialyl-Lewisa and sialyl-Lewisx epitope analogs as E-selection receptors
INVENTOR(S): Oehrlein, Reinhold
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Oehrlein, Reinhold
SOURCE: PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9728174	A1	19970807	WO 1997-EP223	19970117 <--
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9714446	A	19970822	AU 1997-14446	19970117 <--
EP 886639	A1	19981230	EP 1997-901068	19970117 <--
EP 886639	B1	20080528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6187754	B1	20010213	US 1999-117521	19990108 <--
PRIORITY APPLN. INFO.:			CH 1996-229 A	19960130 <--
			WO 1997-EP223 W	19970117 <--

OTHER SOURCE(S): MARPAT 127:205815

GI



I

AB Sialyl-Lewisa and sialyl-Lewisx epitope analogs I (Z = α-pyranose; R1 = H, alkyl, alkenyl, cycloalkyl, heteroaryl, cycloaryl; R2 = alkyl, cycloalkyl; R3 = Me, hydroxymethyl; X = CO, CS, SO2, acyl, thiocarbonyl) in which the naturally occurring N-acetyl group of the N-acetylglucosamine monomer is replaced by various aliphatic or aromatic substituents and the L-fucose naturally present is replaced by various naturally occurring or non-naturally occurring sugars were prepared as E-selectin receptors. Thus, I (R = Me, R1 = 2-hydroxy-5-fluorophenyl, X = CO, R2 = (CH2)8CO2Me, Z = R3) was prepared and tested as E-selectin receptor (relative IC50 to an internal control is 0.039).

IT 194655-09-9P

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sialyl-Lewisa and sialyl-Lewisx epitope analogs as E-selection receptors)

RN 194655-09-9 HCAPLUS

CN Nonanoic acid, 9-[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-(1→4)-O-[6-deoxy-α-L-galactopyranosyl-(1→3)]-2-deoxy-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]amino]-β-D-glucopyranosyl]oxy]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 194655-11-3P 194655-12-4P
RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sialyl-Lewisa and sialyl-Lewisx epitope analogs as E-selection receptors)
RN 194655-11-3 HCAPLUS
CN Nonanoic acid, 9-[[2-deoxy-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]amino]-4-O-β-D-galactopyranosyl-β-D-glucopyranosyl]oxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 194655-12-4 HCAPLUS
CN Nonanoic acid, 9-[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-(1→4)-2-deoxy-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]amino]-β-D-glucopyranosyl]oxy]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 194655-10-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sialyl-Lewisa and sialyl-Lewisx epitope analogs as E-selection receptors)
RN 194655-10-2 HCAPLUS
CN Nonanoic acid, 9-[[2-deoxy-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]amino]-β-D-glucopyranosyl]oxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:958268 HCAPLUS Full-text
DOCUMENT NUMBER: 123:350253
ORIGINAL REFERENCE NO.: 123:62645a,62648a
TITLE: Aerosol drug formulations containing vitamin E
INVENTOR(S): Fu, Lu Mou-ying; Gupta, Pramod K.; Adjei, Akwete L.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9524892	A1	19950921	WO 1995-US2764	19950302 <--
W: AU, CA, JP, KR, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2183557	A1	19950921	CA 1995-2183557	19950302 <--
AU 9519804	A	19951003	AU 1995-19804	19950302 <--
AU 709783	B2	19990909		
JP 09510445	T	19971021	JP 1995-524061	19950302 <--
EP 804157	A1	19971105	EP 1995-912746	19950302 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				

PRIORITY APPLN. INFO.: US 1994-212472 A 19940314 <--
WO 1995-US2764 W 19950302 <--

AB Pharmaceutical compns. for aerosol delivery are disclosed comprising (a) a medicament, (b) a non-chlorofluorocarbon propellant, and (c) tocopherol or a pharmaceutically acceptable derivative thereof, as well as a method for preparing such compns. in which unwanted aggregation of the medicament is prevented without the use of surfactants or cosolvents. Pharmaceutical aerosols containing leuprolide acetate in 0.1% d-α tocopheryl acetate (I) and 10mL HFC-134a were prepared having good dispersion quality as compared with controls without I which had poor dispersion quality.

IT 170929-31-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aerosol drug formulations containing vitamin E)

RN 170929-31-4 HCAPLUS
CN D-Alaninamide, N-acetyl-3-(1-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-O-(1-oxohexadecyl)-D-seryl-N-methyl-L-tyrosyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L46 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:173516 HCAPLUS Full-text
DOCUMENT NUMBER: 116:173516
ORIGINAL REFERENCE NO.: 116:29355a,29358a
TITLE: Supramolecular asymmetric induction with a NADH model reagent grafted on silica
AUTHOR(S): Losset, D.; Dupas, G.; Duflos, J.; Bourguignon, J.; Queguiner, G.
CORPORATE SOURCE: Lab. Chim. Org. Fine Heterocyclique, INSA, Mont-Saint Aigman, 76131, Fr.
SOURCE: Bulletin de la Societe Chimique de France (1991), (Sept.-Oct.), 721-9
CODEN: BSCFAS; ISSN: 0037-8968
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 116:173516

AB A model of NADH issued from a thieno[2,3-b]dihydropyridine derivative has been grafted onto a silica matrix bearing on another part a chiral auxiliary. Two strategies were implemented to obtain the corresponding reagents. In the first case, the reagent and the auxiliary were grafted to the silica by means of two different arms. In the second case, the reagent and the auxiliary were linked to two arms which are brought together before being linked to the silica matrix. The reagents thus obtained were involved in the reduction of Me phenylglyoxylate and enantiomeric excesses of 20 and 35% were obtained.

IT 140168-98-5DP, silica-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation and reduction of)
RN 140168-98-5 HCAPLUS
CN Thieno[2,3-b]pyridinium, 5-(aminocarbonyl)-7-[15-[(hydroxydimethylsilyl)methyl]-33-methyl-13,16,29-trioxo-32-(phenylmethyl)-12,17,30-trioxa-33-azatetratriacont-1-yl]-, bromide (9CI) (CA INDEX NAME)



L46 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:84168 HCAPLUS Full-text
DOCUMENT NUMBER: 112:84168
ORIGINAL REFERENCE NO.: 112:14247a,14250a
TITLE: Stable ethanolamine derivatives-cyclodextrin inclusion compounds as blood platelet aggregation inhibitors
INVENTOR(S): Kitazoe, Sawako; Nakakame, Fujio; Honda, Haruo
PATENT ASSIGNEE(S): Terumo Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01121253	A	19890512	JP 1987-280057	19871105 <--
PRIORITY APPLN. INFO.:			JP 1987-280057	19871105 <--
OTHER SOURCE(S):	MARPAT 112:84168			

GI



AB The title cyclodextrin inclusion compds. contain an ethanolamine R1NH(CH2)2OR2[R1 = H, acyl (from nicotinic acid, triene or pentaene higher fatty acid); R2 = acyl (from nicotinic acid, triene or pentaene higher fatty

acid)]. A solution of an ethanolamine I in EtOH was treated with β-cyclodextrin in H2O to give an inclusion compound, which was kept at 40° for 30 days to show 95% intact I.

IT 125274-67-1P

RL: PREP (Preparation)
(preparation of, as blood platelet aggregation inhibitor)

RN 125274-67-1 HCAPLUS

CN β-Cyclodextrin, compd. with (Z,Z,Z)-2-[(3-pyridinylcarbonyl)amino]ethyl 9,12,15-octadecatrienoate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 109001-04-9
CMF C26 H38 N2 O3

Double bond geometry as shown.



CM 2

CRN 7585-39-9
CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A





L46 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:55850 HCAPLUS Full-text
DOCUMENT NUMBER: 112:55850
ORIGINAL REFERENCE NO.: 112:9599a,9602a
TITLE: N-thiazolylquinolinecarboxamides and analogs as analgesics and antiinflammatory agents, their preparation, and formulations containing them
INVENTOR(S): Clemence, Francois; Le Martret, Odile; Delevallee, Francoise
PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.
SOURCE: U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 831,356, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4845105	A	19890704	US 1987-30680	19870324 <--
FR 2572404	A2	19860502	FR 1984-16573	19841030 <--
FR 2572404	B2	19871211		
FR 2585356	A1	19870130	FR 1985-11389	19850725 <--
FR 2585356	B1	19871023		
US 4735951	A	19880405	US 1985-790064	19851022 <--
ES 556218	A3	19870716	ES 1986-556218	19860619 <--
US 4988708	A	19910129	US 1988-183911	19880420 <--

PRIORITY APPLN. INFO.:

FR 1984-16573	A	19841030 <--
FR 1985-11389	A	19850725 <--
US 1985-790064	A2	19851022 <--
US 1986-831356	A2	19860220 <--
US 1986-890081	A1	19860724 <--
GB 1977-18597	A	19770504 <--
FR 1982-9654		19820603 <--
US 1987-30680	A2	19870324 <--

OTHER SOURCE(S): MARPAT 112:55850
GI



I

AB The title compds. I (X = H, halo, C1-5 alkyl, etc., in the 5-, 6-, 7-, or 8-position; R1 = H, C1-4 alkyl; R2 = thiazolyl, 4,5-dihydrothiazolyl, pyridinyl, oxazolyl, etc.; A = CR3R4OCOR5, etc.; R3, R4 = H, C1-4 alkyl, aryl; R5 = Ph,

naphthyl, etc.), useful as analgesics and antiinflammatory agents, were prepared A mixture of 4-hydroxy-2-(1-propenyl)-N-(2-thiazolyl)-8-trifluoromethyl-3- quinolinecarboxamide, methylbenzyl ammonium chloride, and KMnO4 in CH2Cl2 was stirred at 0° for 1 h to give 2-(1,2-dihydroxypropyl)-4-hydroxy- N-(2-thiazolyl)-8-trifluoromethyl-3-quinolinecarboxamide (II). In a chronic arthritis test using rats, II exhibited an oral ED50 of 3 mg/kg. Tablet formulations contg I were given.

IT 124822-98-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as analgesic and antiinflammatory agent)

RN 124822-98-6 HCAPLUS

CN Dodecanoic acid, 1-[4-hydroxy-3-[(2-thiazolylamino)carbonyl]-8-(trifluoromethyl)-2-quinolinyl]propyl ester (CA INDEX NAME)



L46 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:422828 HCAPLUS Full-text

DOCUMENT NUMBER: 109:22828

ORIGINAL REFERENCE NO.: 109:3897a,3900a

TITLE: 4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities

AUTHOR(S): Clemence, Francois; Le Martret, Odile; Delevallee, Francoise; Benzoni, Josette; Jouanen, Alain; Jouquey, Simone; Mouren, Michel; Deraedt, Roger

CORPORATE SOURCE: Cent. Rech., ROUSSEL-UCLAF, Romainville, 93230, Fr.

SOURCE: Journal of Medicinal Chemistry (1988), 31(7), 1453-62
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 109:22828

GI



I

AB A series of 4-hydroxy-3-quinolinecarboxamides were synthesized and evaluated by the oral route as antiinflammatory agents in carrageenin-induced foot edema and adjuvant-induced arthritis and as analgesic agents in the AcOH induced writhing test. Thus, 4-hydroxy-8-methoxy-3-quinolinecarbonyl chloride reacted with 2-aminothiazole to give 64% the title compound I (R = MeO, R1 = H). Some

of the most active mols., possessed both analgesic and acute antiinflammatory activity, others, such as I (R = CF3; R1 = H, Me, CHCl2) were only powerful, peripherally acting analgesics. I (R = CF3, R1 = CHCl2), being active at 1 mg/kg (ED50), is the most potent compound in the series. Some analogs, substituted in the 2-position by an alc., ester, or amine function, displayed potent antiarthritic activity in the same range as that of piroxicam and were also active in acute tests of inflammation and nociception. They inhibited the activity of both cyclooxygenase and 5-lipoxygenase at micromolar concns. I (R = CF3, R1 = EtCO2CHEt) (RU 43526) showed potent antiarthritic activity (adjuvant-induced arthritis, ED50 = 0.7 mg/kg, po) and gastrointestinal tolerance (ED100 > 250 mg/kg, po) and thus it is presently undergoing an extensive pharmacol. evaluation.

IT 124822-98-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and analgesic activity of)

RN 124822-98-6 HCAPLUS

CN Dodecanoic acid, 1-[4-hydroxy-3-[(2-thiazolylamino)carbonyl]-8-(trifluoromethyl)-2-quinolinyl]propyl ester (CA INDEX NAME)



L46 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1987:439501 HCAPLUS Full-text

DOCUMENT NUMBER: 107:39501

ORIGINAL REFERENCE NO.: 107:6595a,6598a

TITLE: Alkenoylaminoalkanol and nicotinoylaminoalkanol derivatives as inhibitors of platelet aggregation

INVENTOR(S): Takahashi, K.; Suwabe, Y.; Wakabayashi, T.

PATENT ASSIGNEE(S): Terumo Corp., Japan

SOURCE: Belg., 37 pp.
CODEN: BEXXAL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 901987	A1	19850716	BE 1985-214681	19850321 <--
JP 60197642	A	19851007	JP 1984-53796	19840321 <--
JP 01013703	B	19890307		
JP 61189252	A	19860822	JP 1985-26533	19850215 <--
JP 03021540	B	19910322		
US 4619938	A	19861028	US 1985-713496	19850319 <--
EP 161422	A1	19851121	EP 1985-103253	19850320 <--
EP 161422	B1	19890301		

R: CH, DE, FR, GB, LI, NL, SE

PRIORITY APPLN. INFO.: JP 1984-53796 A 19840321 <--
JP 1985-26533 A 19850215 <--
OTHER SOURCE(S): CASREACT 107:39501; MARPAT 107:39501
GI



II

AB The title compds. R1R2N(CH2)nOR3 [R1 = H, alkyl, R2 = H, acyl radical (from nicotinic acid, trienoic or pentaenoic fatty acids); R3 = R2, 3-pyridylmethyl; n = 2-3], useful as platelet aggregation inhibitors, were prepared A solution of 302 mg 5,8,11,14,17-eicosapentaenoic acid in CHCl3 was treated with 0.13 mL (COCl)2. The resulting eicosapentaenoyl chloride reacted with 753 mg H2N(CH2)3OH in anhydrous CHCl3 containing 276 mg K2CO3 for 2 h to give 243 ng N-(5,8,11,14,17-eicosapentaenoyl)-3-aminopropanol (I). I was esterified at room temperature with nicotinoyl chloride in anhydrous C6H6 in the presence of K2CO3 to yield the corresponding N-eicosapentaenoyl-3- aminopropyl nicotinate II. At 3.44 + 10-6 M, II provided 50% in vitro inhibition of rabbit blood platelet aggregation induced by arachidonic acid (100 μmol). Tablets containing II, cellulose, corn starch, lactose, hydroxypropylcellulose, Mg stearate, etc., were prepared

IT 109001-04-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as blood platelet aggregation inhibitor)

RN 109001-04-9 HCAPLUS

CN 9,12,15-Octadecatrienoic acid, 2-[(3-pyridinylcarbonyl)amino]ethyl ester, (Z,Z,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L46 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:468012 HCAPLUS Full-text
DOCUMENT NUMBER: 95:68012
ORIGINAL REFERENCE NO.: 95:11387a,11390a
TITLE: Soft quaternary surface active agents and method of using same
INVENTOR(S): Bodor, Nicolae S.
PATENT ASSIGNEE(S): INTERx Research Corp., USA
SOURCE: U.S., 24 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4204065	A	19800520	US 1978-969255	19781213 <--
US 3989711	A	19761102	US 1975-615519	19750922 <--
PRIORITY APPLN. INFO.:			US 1975-615519	A2 19750922 <--
			US 1976-726841	A1 19760927 <--

GI



I

AB Soft quaternary ammonium surface active agents .tplbond.N+CHRO2CR1 X- (.tplbond.N+ from open chain or cyclic amines, R = H, C1-20 alkyl or cycloalkyl, alkoxyalkyl, acyloxyalkyl, haloalkyl, or carboxyalkyl, substituted aryl groups, R1 = C9-22 alkyl, alkylamine groups and X = halogen atom or monovalent anion) exhibit antibacterial activity with low toxicity and are used in mouthwashes, shampoos and other formulations. 1-n-Dodecanoyloxymethyl-3-methylimidazolium chloride (I) [61413-61-4] was prepared from chloromethyl n-dodecanoate [61413-67-0] and 1-methylimidazole [616-47-7]. The i.p., i.v., and oral LD50 doses for I were resp., 14-16, 3-4.5 and 40 times higher than those observed for cetylpyridinium chloride.

IT 61413-66-9 78472-32-9 78472-33-0
78472-38-5 78472-41-0 78472-42-1
78472-48-7 78472-49-8 78472-50-1
78472-51-2 78472-56-7 78472-57-8
78472-58-9 78472-59-0 78472-63-6
78472-64-7 78472-65-8 78472-68-1
78472-69-2 78472-70-5 78472-71-6
78472-76-1 78472-77-2 78472-78-3
78472-79-4 78492-60-1 78492-62-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericide)

RN 61413-66-9 HCAPLUS

CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[[(1-oxododecyl)oxy]methyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-32-9 HCAPLUS

CN Pyridinium, 3-(aminocarbonyl)-1-[[(1-oxooctyl)oxy]methyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-33-0 HCAPLUS

CN Pyridinium, 3-(aminocarbonyl)-1-[[(1-oxooctyl)oxy]methyl]-, bromide (9CI) (CA INDEX NAME)



RN 78472-38-5 HCAPLUS

CN Pyridinium, 3-(aminocarbonyl)-1-[[(1-oxodecyl)oxy]methyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-41-0 HCAPLUS

CN Pyridinium, 3-(aminocarbonyl)-1-[[(1-oxotetradecyl)oxy]methyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-42-1 HCAPLUS
CN Pyridinium, 3-(aminocarbonyl)-1-[[(1-oxotetradecyl)oxy]methyl]-, bromide (9CI) (CA INDEX NAME)



RN 78472-48-7 HCAPLUS
CN Pyridinium, 3-(aminocarbonyl)-1-[1-[(1-oxooctyl)oxy]ethyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-49-8 HCAPLUS
CN Pyridinium, 3-(aminocarbonyl)-1-[1-[(1-oxooctyl)oxy]ethyl]-, bromide (9CI) (CA INDEX NAME)



RN 78472-50-1 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[1-[(1-oxooctyl)oxy]ethyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-51-2 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[1-[(1-oxooctyl)oxy]ethyl]-, bromide (9CI) (CA INDEX NAME)



RN 78472-56-7 HCAPLUS
CN Pyridinium, 3-(aminocarbonyl)-1-[1-[(1-oxodecyl)oxy]ethyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-57-8 HCAPLUS
CN Pyridinium, 3-(aminocarbonyl)-1-[1-[(1-oxodecyl)oxy]ethyl]-, bromide (9CI) (CA INDEX NAME)



RN 78472-58-9 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[1-[(1-oxodecyl)oxy]ethyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-59-0 HCAPLUS

CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[1-[(1-oxodecyl)oxy]ethyl]-, bromide (9CI) (CA INDEX NAME)



RN 78472-63-6 HCAPLUS

CN Pyridinium, 3-(aminocarbonyl)-1-[1-[(1-oxododecyl)oxy]ethyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-64-7 HCAPLUS

CN Pyridinium, 3-(aminocarbonyl)-1-[1-[(1-oxododecyl)oxy]ethyl]-, bromide (9CI) (CA INDEX NAME)



RN 78472-65-8 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[1-[(1-oxododecyl)oxy]ethyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-68-1 HCAPLUS
CN Pyridinium, 3-(aminocarbonyl)-1-[1-[(1-oxohexadecyl)oxy]ethyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-69-2 HCAPLUS
CN Pyridinium, 3-(aminocarbonyl)-1-[1-[(1-oxohexadecyl)oxy]ethyl]-, bromide (9CI) (CA INDEX NAME)



RN 78472-70-5 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[1-[(1-oxohexadecyl)oxy]ethyl]-, chloride (9CI) (CA INDEX NAME)



RN 78472-71-6 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[1-[(1-oxohexadecyl)oxy]ethyl]-, bromide (9CI) (CA INDEX NAME)



RN 78472-76-1 HCAPLUS
CN Pyridinium, 3-(aminocarbonyl)-1-[[(1-oxo-9-octadecenyl)oxy]methyl]-, chloride, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 78472-77-2 HCAPLUS
CN Pyridinium, 3-(aminocarbonyl)-1-[[(1-oxo-9-octadecenyl)oxy]methyl]-, bromide, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 78472-78-3 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[[(1-oxo-9-octadecenyl)oxy]methyl]-, chloride, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 78472-79-4 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[[(1-oxo-9-octadecenyl)oxy]methyl]-, bromide, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 78492-60-1 HCAPLUS
CN Pyridinium, 3-(aminocarbonyl)-1-[[(1-oxodecyl)oxy]methyl]-, bromide (9CI) (CA INDEX NAME)



RN 78492-62-3 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[1-[(1-oxododecyl)oxy]ethyl]-, bromide (9CI) (CA INDEX NAME)



L46 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:191861 HCAPLUS Full-text
DOCUMENT NUMBER: 92:191861
ORIGINAL REFERENCE NO.: 92:31009a,31012a

TITLE: Soft drugs. 1. Labile quaternary ammonium salts as soft antimicrobials
AUTHOR(S): Bodor, Nicholas; Kaminski, James J.; Selk, Sally
CORPORATE SOURCE: Coll. Pharm., Univ. Florida, Gainesville, FL, 32610, USA
SOURCE: Journal of Medicinal Chemistry (1980), 23(5), 469-74
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB The title compds., defined as biol. active chemical compds. (drugs), are characterized by a predictable in vivo destruction (metabolism) to nontoxic moieties, after they achieve their therapeutic role, were prepared by direct quaternization of the appropriate amine with an α-haloalkyl ester (soft alkylating agent). 1-[(Dodecanoyloxy)methyl]-3-methylimidozolium chloride (I) [61413-61-4] was about 10 times less active as an antimicrobial than the control hexadecylpyridinium chloride. However, I was still effective at 0.1 and 0.01%, a concentration which is less than that at which the control is generally used; in the same time I was 15-40% times less toxic than the control. The LD50 of I i.p., i.v., and orally was determined in mice. The alkyl chain length and the nature of the amine affect antimicrobial activity.

IT 61413-66-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antimicrobial activity of)

RN 61413-66-9 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[[(1-oxododecyl)oxy]methyl]-, chloride (9CI) (CA INDEX NAME)



L46 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:557420 HCAPLUS Full-text
DOCUMENT NUMBER: 91:157420
ORIGINAL REFERENCE NO.: 91:25401a,25404a
TITLE: Labile, non-heterocyclic quaternary ammonium

salt-esters as transient derivatives
INVENTOR(S): Bodor, Nicolae S.
PATENT ASSIGNEE(S): INTERx Research Corp., USA
SOURCE: U.S., 46 pp. Cont.-in-part of U.S. 3,998,815.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4160099	A	19790703	US 1976-724914	19760920 <--
US 3998815	A	19761221	US 1974-482513	19740624 <--
CA 1045628	A1	19790102	CA 1975-229912	19750623 <--
FR 2276289	A1	19760123	FR 1975-19766	19750624 <--
FR 2276289	B1	19791019		
AU 7582412	A	19770106	AU 1975-82412	19750624 <--
GB 1471828	A	19770427	GB 1975-26734	19750624 <--
US 4727151	A	19880223	US 1978-962948	19781122 <--

PRIORITY APPLN. INFO.: US 1974-482513 A2 19740624 <--
US 1976-724914 A3 19760920 <--
OTHER SOURCE(S): CASREACT 91:157420; MARPAT 91:157420

AB Title compds., which readily hydrolyze chemical or enzymatically to release a tertiary amine and other compds., as well as heterocyclic analogs with similar properties., were prepared by quaternization of the corresponding tertiary amine. Thus, Et2NCH2CONHC6H3Me2-2,6 treated with Me3CCO2CH2Cl gave 80% (Me3CCO2CH2)Et2N+CH2CONHC6H3Me2-2,6 Cl-. Pilocarpine (I) was quaternized similarly with Me(CH2)14CO2CH2Cl to give a quaternary salt which released I in the eyes of albino rabbits at a higher and more sustained rate than I.HCl.

IT 61413-66-9P 71221-87-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 61413-66-9 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[[(1-oxododecyl)oxy]methyl]-, chloride (9CI) (CA INDEX NAME)



RN 71221-87-9 HCAPLUS
CN Pyridinium, 3-[(dimethylamino)carbonyl]-1-[[(1-oxododecyl)oxy]methyl]-, chloride (9CI) (CA INDEX NAME)



L46 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1977:57135 HCAPLUS Full-text
DOCUMENT NUMBER: 86:57135
ORIGINAL REFERENCE NO.: 86:9117a,9120a
TITLE: Soft quaternary surface active agents exhibiting antibacterial activity
INVENTOR(S): Bodor, Nicolae S.
PATENT ASSIGNEE(S): Interx Research Corp., USA
SOURCE: U.S., 24 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3989711	A	19761102	US 1975-615519	19750922 <--
DE 2641896	A1	19770421	DE 1976-2641896	19760917 <--
FR 2324721	A1	19770415	FR 1976-28340	19760921 <--
JP 52039616	A	19770328	JP 1976-113206	19760922 <--
US 4204065	A	19800520	US 1978-969255	19781213 <--
US 4313889	A	19820202	US 1980-158316	19800610 <--
PRIORITY APPLN. INFO.:			US 1975-615519 A	19750922 <--
			US 1976-726841 A1	19760927 <--
			US 1978-969260 A1	19781213 <--

AB Ten quaternary ammonium compds. useful as antibacterial agents in detergents, mouthwashes, shampoos, cosmetic bases, etc., were prepared by the reaction of Me(CH2)nCO2CH2Cl (n = 6, 10, 12, or 14) with pyridine [110-86-1], 1-methylimidazole [616-47-7], Et3N [121-44-8], triethylenediamine [280-57-9], or N-ethylnicotinamide [4314-66-3]. The quaternary compds. degraded into nontoxic by-products after use. Thus, Me(CH2)6CO2CH2Cl [61413-70-5] and pyridine were heated at 90° for 3 hr to prepare N-(octanoyloxymethyl)pyridinium chloride [61413-57-8].

IT 61413-66-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericide, surface-active, biodegradable)

RN 61413-66-9 HCAPLUS
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[[(1-oxododecyl)oxy]methyl]-, chloride (9CI) (CA INDEX NAME)



L46 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:49557 HCAPLUS Full-text
DOCUMENT NUMBER: 68:49557
ORIGINAL REFERENCE NO.: 68:9595a,9598a
TITLE: Flavine-pyridinium biscoenzyme analogs. Synthesis and reactivity
AUTHOR(S): Pappas, Socrates P.; Pappas, Betty C.; Marchant, Kerford A., Jr.
CORPORATE SOURCE: Emory Univ., Atlanta, GA, USA
SOURCE: Biochemistry (1967), 6(10), 3264-9
CODEN: BICHAW; ISSN: 0006-2960
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB The potential importance of flavine-pyridinium interactions in enzymic reactions catalyzed by flavoproteins prompted the synthesis of substances, embodying both a flavine and pyridinium group separated by a varying number of atoms, for study as model enzymes. The synthesis of flavine 3-carbamidopyridinium models (I) with connecting links of 14, 9, and 7 atoms between the terminal flavine and pyridinium moieties is reported. The kinetics of the nonenzymatic oxidation of NADH and dihydrolipoic acid [Lip(SH)2] by these substances were determined In all cases, rate enhancements of two- to sevenfold relative to riboflavin were observed. The results provide kinetic evidence for different mechanisms of participation by the pyridinium rings of the models in the oxidation of NADH and Lip(SH)2. In the latter case, the rate increases which parallel closer proximity of the terminal flavin and pyridinium groups apparently reflect enhanced electronegativity of the flavine ring. However, in the oxidation of NADH, the relative rates, representative activation parameters, and control expts. indicate that the pyridinium ring actively participates in the transition state of the reductive process by coordination with the flavine ring or with NADH.
IT 17334-98-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 17334-98-4 HCAPLUS
CN Pyridinium, 3-carbamoyl-1-(10-carboxydecyl)-, bromide, ester with 10-(2-hydroxyethyl)-7,8-dimethylisoalloxazine (8CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L46 ANSWER 14 OF 16 USPATFULL on STN

ACCESSION NUMBER:	2001:22200 USPATFULL Full-text			
TITLE:	Sialyl-Lewisa and sialyl-Lewisx epitode analogues			
INVENTOR(S):	Oehrlein, Reinhold, Rheinfelden, Germany, Federal Republic of			
PATENT ASSIGNEE(S):	GlycoTech Corp., Rockville, MD, United States (U.S. corporation)			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6187754	B1	20010213	<--
	WO 9728174		19970807	<--
APPLICATION INFO.:	US 1999-117521		19990108	(9)
	WO 1997-EP223		19970117	
			19990108	PCT 371 date
			19990108	PCT 102(e) date
	NUMBER		DATE	
PRIORITY INFORMATION:	CH 1996-229		19960130	<--
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Fonda, Kathleen K.			
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC			
NUMBER OF CLAIMS:	46			
EXEMPLARY CLAIM:	1			

LINE COUNT: 2678

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sialyl-Lewis.sup.a and sialyl-Lewis.sup.x epitope analogues, in which the natural N-acetyl group of the N-acetylglucosamine monomer is replaced by various hydroxylated aromatic substituents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 194655-09-9P

(preparation of sialyl-Lewisa and sialyl-Lewisx epitope analogs as E-selection receptors)

RN 194655-09-9 USPATFULL

CN Nonanoic acid, 9-[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-(1→4)-O-[6-deoxy-α-L-galactopyranosyl-(1→3)]-2-deoxy-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]amino]-β-D-glucopyranosyl]oxy]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 194655-11-3P 194655-12-4P

(preparation of sialyl-Lewisa and sialyl-Lewisx epitope analogs as E-selection receptors)

RN 194655-11-3 USPATFULL
CN Nonanoic acid, 9-[[2-deoxy-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]amino]-4-O-β-D-galactopyranosyl-β-D-glucopyranosyl]oxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 194655-12-4 USPATFULL
CN Nonanoic acid, 9-[[O-(N-acetyl-α-neuraminosyl)-(2→3)-O-β-D-galactopyranosyl-(1→4)-2-deoxy-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]amino]-β-D-glucopyranosyl]oxy]-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 194655-10-2P
(preparation of sialyl-Lewisa and sialyl-Lewisx epitope analogs as E-selection receptors)
RN 194655-10-2 USPATFULL
CN Nonanoic acid, 9-[[2-deoxy-2-[[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]amino]-β-D-glucopyranosyl]oxy]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L46 ANSWER 15 OF 16 USPATFULL on STN
ACCESSION NUMBER: 86:60823 USPATFULL Full-text
TITLE: Fatty acid derivatives of aminoalkyl nicotinic acid esters and platelet aggregation inhibitors
INVENTOR(S): Takahashi, Keiko, Tokyo, Japan
Suwabe, Yasushi, Tokyo, Japan
Wakabayashi, Toshio, Tama, Japan
PATENT ASSIGNEE(S): Terumo Kabushiki Kaisha, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4619938		19861028	<--
APPLICATION INFO.:	US 1985-713496		19850319	(6)

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1984-53796	19840321	<--
	JP 1985-26533	19850215	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Jiles, Henry R.
ASSISTANT EXAMINER: Bjorkman, Dale A.
LEGAL REPRESENTATIVE: Burns, Doane, Swecker and Mathis
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1,5
LINE COUNT: 792
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Alkanolamine derivatives and platelet aggregation inhibitors containing the same as an active ingredient are disclosed. The alkanolamine derivatives are novel compounds which possess potent platelet aggregation inhibitory activities and effective in preventing diseases such as thrombosis. As typical compounds are mentioned N-5,8,11,14,17-eicosapentaenoyl-2-aminoethanol, N-nicotinoyl-2- aminoethyl-5,8,11,14,17-eicosapentaenoate, N-ethyl-N-5,8,11,14,17- eicosapentaenoyl-2-aminoethanol, N-butyl-N-5,8,11,14,17-eicosapentaenoyl- 2-aminoethanol, N-5,8,11,14,17-3-aminopropylnicotinate, (N-ethyl-N-nicotinoyl-2-aminoethyl)-5,8,11,14,17-eicosapentaenoate and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 109001-04-9P
(preparation of, as blood platelet aggregation inhibitor)
RN 109001-04-9 USPATFULL
CN 9,12,15-Octadecatrienoic acid, 2-[(3-pyridinylcarbonyl)amino]ethyl ester, (Z,Z,Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L46 ANSWER 16 OF 16 USPATFULL on STN

ACCESSION NUMBER:	82:5735 USPATFULL Full-text
TITLE:	Soft quaternary surface active agents
INVENTOR(S):	Bodor, Nicolae S., Lawrence, KS, United States
PATENT ASSIGNEE(S):	Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4313889		19820202	<--
APPLICATION INFO.:	US 1980-158316		19800610 (6)	

RELATED APPLN. INFO.: Continuation of Ser. No. US 1978-969260, filed on 13 Dec 1978, now abandoned which is a division of Ser. No. US 1976-726841, filed on 27 Sep 1976, now Defensive Publication No. which is a continuation-in-part of Ser. No. US 1975-615519, filed on 22 Sep 1975, now patented, Pat. No. US 3989711

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Niebling, John F.
LEGAL REPRESENTATIVE:	Sudol, Jr., Michael C.
NUMBER OF CLAIMS:	50
EXEMPLARY CLAIM:	1
LINE COUNT:	1071

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft quaternary surface active agents having the formula: ##STR1## wherein ##STR2## represents a tertiary open chain or cyclic aliphatic amine; wherein ##STR3## represents an unsaturated amine; wherein R represents a member selected from the group consisting of a hydrogen atom, a C.sub.1 -C.sub.20 open chain or cyclo alkyl group, a C.sub.1 -C.sub.20 alkoxyalkyl group, a C.sub.1 -C.sub.20 acyloxyalkyl group, a C.sub.1 -C.sub.20 haloalkyl group, a C.sub.1 -C.sub.20 carboxyalkyl group, an aryl group, and a substituted aryl group, whose substituents are selected from the group consisting of a halogen atom, an O--C.sub.1 -C.sub.4 alkyl group, an O--C.sub.1 -C.sub.8 acyl group, a nitro group, a carboxyl group, and a carboethoxy group; wherein R.sub.1 represents a C.sub.9 -C.sub.22 straight or branched alkyl group, a --(CH.sub.2).sub.n -- ##STR4## wherein R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each selected from the group consisting of a hydrogen atom, a methyl group or an ethyl group, a C.sub.0 -C.sub.22 straight or branched alkyl ##STR5## wherein n in each occurrence and m represent an integer of from 0 to 22, an ##STR6## wherein A represents a C.sub.0 -C.sub.22 straight or branched alkyl group as above or a --(CH.sub.2 CH.sub.2 O).sub.p group, wherein the p represents an integer of from 0 to 22, and the residue of any naturally occurring bile acid or synthetic derivative thereof; and wherein X represents a halogen atom or any other organic or inorganic monovalent anion are disclosed.

All compounds encompassed within the above-described generic formulae find use as "soft" antibacterial agents of extremely low toxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 61413-66-9
(bactericide, surface-active, biodegradable)
RN 61413-66-9 USPATFULL
CN Pyridinium, 3-[(ethylamino)carbonyl]-1-[[(1-oxododecyl)oxy]methyl]-, chloride (9CI) (CA INDEX NAME)



SEARCH HISTORY

=> d his ful

```
     (FILE 'HOME' ENTERED AT 13:45:16 ON 19 JUN 2008)

     FILE 'HCAPLUS' ENTERED AT 13:45:46 ON 19 JUN 2008
                E WEIDNER MORTEN SLOTH/AU
L1           23 SEA ABB=ON  "WEIDNER MORTEN SLOTH"/AU
L2            1 SEA ABB=ON  L1 AND ?POLYHYDROXYALKAN?
                SELECT RN L2 1

     FILE 'REGISTRY' ENTERED AT 13:46:24 ON 19 JUN 2008
L3           29 SEA ABB=ON  (59-67-6/BI OR 10417-94-4/BI OR 107-88-0/BI OR
                110-86-1/BI OR 114-33-0/BI OR 124-07-2/BI OR 141-22-0/BI OR
                142-62-1/BI OR 143-07-7/BI OR 329-89-5/BI OR 334-48-5/BI OR
                373-49-9/BI OR 4314-66-3/BI OR 4621-66-3/BI OR 463-40-1/BI OR
                50-70-4/BI OR 502-54-5/BI OR 506-26-3/BI OR 513-85-9/BI OR
                544-63-8/BI OR 544-64-9/BI OR 56-81-5/BI OR 57-10-3/BI OR
                57-55-6/BI OR 60-33-3/BI OR 6217-54-5/BI OR 6556-11-2/BI OR
                7150-23-4/BI OR 98-92-0/BI)

     FILE 'HCAPLUS' ENTERED AT 13:46:30 ON 19 JUN 2008
L4            1 SEA ABB=ON  L2 AND L3

     FILE 'REGISTRY' ENTERED AT 13:47:30 ON 19 JUN 2008
                E NIACINAMIDE/CN
L5            1 SEA ABB=ON  NIACINAMIDE/CN
L6            1 SEA ABB=ON  98-92-0/RN
L7              STRUCTURE 98-92-0
L8            0 SEA SSS SAM L7
L9            0 SEA SSS FUL L7
L10             STR L7
L11           0 SEA SSS SAM L10
                E GLYCERYLMONOCAPRYLATE/CN
                E 1-GLYCERYLMONOCAPRYLATE/CN
                E 1-GLYCERYL MONOCAPRYLATE/CN
L12             STR L7
L13           0 SEA SSS SAM L12
L14           6 SEA SSS FUL L12
L15           0 SEA ABB=ON  504-54-5/RN
L16           1 SEA ABB=ON  502-54-5/RN

     FILE 'HCAPLUS' ENTERED AT 13:59:47 ON 19 JUN 2008
L17           2 SEA ABB=ON  L6 AND L16
L18           2 SEA ABB=ON  ?NIACINAMID? AND ?GLYCER?(W)?MONOCAPRYLAT?
L19           4 SEA ABB=ON  L17 OR L18

     FILE 'REGISTRY' ENTERED AT 14:02:00 ON 19 JUN 2008
L20          46 SEA ABB=ON  (3030-30-6/BI OR 101828-21-1/BI OR 104153-37-9/BI
                OR 107-11-9/BI OR 110588-57-3/BI OR 112-38-9/BI OR 114-33-0/BI
                OR 119006-77-8/BI OR 126-07-8/BI OR 137234-62-9/BI OR 138674-26
                -7/BI OR 1400-61-9/BI OR 153301-19-0/BI OR 171228-49-2/BI OR
                198022-65-0/BI OR 22916-47-8/BI OR 23593-75-1/BI OR 2398-96-1/B
                I OR 27220-47-9/BI OR 27523-40-6/BI OR 29342-05-0/BI OR
                329-89-5/BI OR 4314-66-3/BI OR 4621-66-3/BI OR 53969-01-0/BI
                OR 59-67-6/BI OR 60628-96-8/BI OR 61318-90-9/BI OR 64211-45-6/B
                I OR 64872-76-0/BI OR 65277-42-1/BI OR 65472-88-0/BI OR
                65899-73-2/BI OR 67-97-0/BI OR 67914-69-6/BI OR 67915-31-5/BI
```

```
                OR 7150-23-4/BI OR 72479-26-6/BI OR 7553-56-2/BI OR 777-11-7/BI
                 OR 78613-35-1/BI OR 84625-61-6/BI OR 86386-73-4/BI OR
                91161-71-6/BI OR 98-92-0/BI OR 99592-32-2/BI)

     FILE 'HCAPLUS' ENTERED AT 14:02:05 ON 19 JUN 2008
L21           4 SEA ABB=ON  L19 AND L20

     FILE 'REGISTRY' ENTERED AT 14:06:00 ON 19 JUN 2008
L22             STR L7
L23             STR L12
L24             STR L7
L25           0 SEA SSS SAM L24
L26             STR L24
L27           0 SEA SSS SAM L26

     FILE 'HCAPLUS' ENTERED AT 14:08:45 ON 19 JUN 2008
                DELETE SELECT
                SELECT RN L21 2-3
                DELETE SELECT

     FILE 'REGISTRY' ENTERED AT 14:13:39 ON 19 JUN 2008
L28           1 SEA ABB=ON  137234-62-9/RN
L29           1 SEA ABB=ON  78613-35-1/RN
                E 119006-77-8/RN
L30           1 SEA ABB=ON  119006-77-8/RN
L31           1 SEA ABB=ON  72479-26-6/RN
L32           5 SEA ABB=ON  (110588-57-3 OR 104153-37-9 OR 99592-32-2 OR
                91161-91-6 OR 86386-73-4 OR 84625-61-6)/RN
L33           0 SEA ABB=ON  (67915-31-5 OR 65899-73-2 OR 65277-42-1 OR
                64211-45-6 OR 60628-96-8 OR 27220-47-9 OR 27523-40-6 OR
                29342-05-0 OR 23593-75-1)/R
L34           9 SEA ABB=ON  (67915-31-5 OR 65899-73-2 OR 65277-42-1 OR
                64211-45-6 OR 60628-96-8 OR 27220-47-9 OR 27523-40-6 OR
                29342-05-0 OR 23593-75-1)/RN
L35           8 SEA ABB=ON  (98-92-0 OR 112-38-9 OR 126-07-8 OR 777-11-7 OR
                1400-61-9 OR 2398-96-1 OR 7553-56-2 OR 22916-47-8)/RN
L36             STR L24
L37           3 SEA SSS SAM L36
L38             STR L36
L39           0 SEA SSS SAM L38
L40          65 SEA SSS FUL L38

     FILE 'HCAPLUS' ENTERED AT 14:38:18 ON 19 JUN 2008
L41          14 SEA ABB=ON  L40
L42           4 SEA ABB=ON  L41 AND (?COSMETIC? OR ?SKIN? OR ?DERM? OR
                ?INFLAM?)
L43          14 SEA ABB=ON  L41 OR L42

     FILE 'USPATFULL' ENTERED AT 14:41:20 ON 19 JUN 2008
L44           7 SEA ABB=ON  L41 OR L42

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 14:41:56 ON 19 JUN 2008
L45          17 DUP REMOV L43 L44 (4 DUPLICATES REMOVED)
L46          16 SEA ABB=ON  L45 AND (PRD<20020620 OR PD<20020620)

     FILE HOME

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
```

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jun 2008 VOL 148 ISS 25
FILE LAST UPDATED: 18 Jun 2008 (20080618/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 JUN 2008 HIGHEST RN 1029146-45-9
DICTIONARY FILE UPDATES: 18 JUN 2008 HIGHEST RN 1029146-45-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 19 Jun 2008 (20080619/PD)
FILE LAST UPDATED: 19 Jun 2008 (20080619/ED)
HIGHEST GRANTED PATENT NUMBER: US7389542
HIGHEST APPLICATION PUBLICATION NUMBER: US20080148460
CA INDEXING IS CURRENT THROUGH 19 Jun 2008 (20080619/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 19 Jun 2008 (20080619/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2008